The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.
Products, services, technology
We have four advanced assets: one commercially available in US and parts of Europe QUVIVIQ (daridorexant (insomnia)), one approved by FDA and with a positive CHMP opinion (aprocitentan (rHTN)) and two assets recruiting in phase 3 programs, outlicensed to Viatris (selatogrel (AMI), cenerimod (SLE).
- https://www.idorsia.com
- +41 58 844 00 00
- investor.relations@idorsia.com
- Andrew C. Weiss
